KaiPharm Co., Ltd., Seoul 03759, Korea.
Computer Vision Lab, Department of Computer Science and Engineering, Ewha Womans University, Seoul 03760, Korea.
Int J Mol Sci. 2021 Sep 15;22(18):9983. doi: 10.3390/ijms22189983.
Drug discovery based on artificial intelligence has been in the spotlight recently as it significantly reduces the time and cost required for developing novel drugs. With the advancement of deep learning (DL) technology and the growth of drug-related data, numerous deep-learning-based methodologies are emerging at all steps of drug development processes. In particular, pharmaceutical chemists have faced significant issues with regard to selecting and designing potential drugs for a target of interest to enter preclinical testing. The two major challenges are prediction of interactions between drugs and druggable targets and generation of novel molecular structures suitable for a target of interest. Therefore, we reviewed recent deep-learning applications in drug-target interaction (DTI) prediction and de novo drug design. In addition, we introduce a comprehensive summary of a variety of drug and protein representations, DL models, and commonly used benchmark datasets or tools for model training and testing. Finally, we present the remaining challenges for the promising future of DL-based DTI prediction and de novo drug design.
基于人工智能的药物发现最近备受关注,因为它显著缩短了开发新药所需的时间和成本。随着深度学习 (DL) 技术的进步和药物相关数据的增长,在药物开发过程的各个步骤中都涌现出了许多基于深度学习的方法。特别是,制药化学家在选择和设计有潜力的药物以进入临床前测试方面面临着重大问题。这两个主要的挑战是预测药物与可成药靶标的相互作用和生成适合靶标的新型分子结构。因此,我们回顾了最近在药物-靶标相互作用 (DTI) 预测和从头药物设计方面的深度学习应用。此外,我们介绍了各种药物和蛋白质表示、DL 模型以及常用的基准数据集或工具的全面总结,这些数据集或工具用于模型训练和测试。最后,我们提出了基于深度学习的 DTI 预测和从头药物设计的未来发展所面临的挑战。